Use of statins and risk of myeloproliferative neoplasms - a Danish nationwide case-control study
Autor: | Daniel Tuyet Kristensen, Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Marianne Tang Severinsen, Louise Hur Hannig, Jørn Starklint, Morten Hagemann Hilsøe, Anders Pommer Vallentin, Mette Brabrand, Hans Carl Hasselbalch, Tarec C. El-Galaly, Anne Stidsholt Roug |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Kristensen, D T, Øvlisen, A K, Jakobsen, L H, Severinsen, M T, Hannig, L H, Starklint, J, Hilsøe, M H, Vallentin, A P, Brabrand, M, Hasselbalch, H C, El-Galaly, T C & Roug, A S 2023, ' Use of statins and risk of myeloproliferative neoplasms-a Danish nationwide case-control study ', Blood advances . https://doi.org/10.1182/bloodadvances.2023009784 |
DOI: | 10.1182/bloodadvances.2023009784 |
Popis: | Previous studies have indicated a possible cancer protective effect of statins in solid cancers; however, this has never been investigated for myeloproliferative neoplasms (MPNs). We aimed to investigate the association between statin use and risk of MPNs in a nested nationwide case-control study, using Danish national population registries. Information on statin use was ascertained, using the Danish National Prescription Registry and patients diagnosed with MPNs between 2010-2018 were identified using The Danish National Chronic Myeloid Neoplasia Registry. The association between statin use and MPNs was estimated using age- and sex adjusted odds ratios (ORs) and fully adjusted odds ratios (aORs), adjusting for prespecified confounders. The study population included 3,816 cases with MPNs and 19,080 population controls (5:1) matched on age and sex by incidence density sampling. Overall, 34.9% of cases and 33.5% of controls were ever-users of statins, resulting in a OR for MPN of 1.07 (95% CI: 0.99-1.16) and an aOR of 0.87 (95% CI: 0.80-0.96), respectively. Among cases, 17.2% were categorized as long-term users (≥5 years) compared to 19.0% among controls, yielding an OR for MPN of 0.90 (95% CI: 0.81-1.00) and an aOR of 0.72 (95% CI: 0.64-0.81). Analyzing the effect of cumulative duration of statin use revealed a dose-dependent response and the association was consistent in sex, age, MPN subgroups and across different statin types. Statin use was associated with a significantly lower odds of being diagnosed with an MPN, indicating a possible cancer-preventive effect of statins. The prospective design of our study precludes causal inference. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...